Merck & Co.'s Stock Surges on Higher Sales and Revised Outlook

Merck & Co., Inc.'s stock price rose to $150.78 on September 2, 2026, amid an increase in sales for Q2 2026.

The pharmaceutical company reported a 5% surge in sales to $16.61 billion, with pharmaceutical sales reaching $14.76 billion and Animal Health contributing $1.78 billion, up 8%. The company also revised its 2026 sales outlook to $66.3 billion to $67.3 billion from a prior range of $65.8 billion to $67.0 billion.

The cancer franchise remains the main earnings engine for Merck & Co., with Keytruda and Keytruda Qlex generating $8.37 billion in quarterly sales, roughly half of the company's total revenue.